Intratracheal administration of prostacyclin analogue-incorporated nanoparticles ameliorates the development of monocrotaline and sugen-hypoxia-induced pulmonary arterial hypertension

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 4, 2016, Pages 290-298

  Akagi, Satoshi ^a   Nakamura, Kazufumi ^a   Matsubara, Hiromi ^b   Kondo, Megumi ^a   Miura, Daiji ^a   Matoba, Tetsuya ^c   Egashira, Kensuke ^c   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Drug delivery system; Intratracheal administration; Nanomedicine; Prostacyclin; Pulmonary arterial smooth muscle cells; Pulmonary hypertension

Indexed keywords

BERAPROST; FLUORESCEIN ISOTHIOCYANATE; MONOCROTALINE; NANOCARRIER; PHOSPHATE BUFFERED SALINE; NANOPARTICLE; PROSTACYCLIN;

ADOLESCENT; ADULT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MORPHOLOGY; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; RAT; SCHOOL CHILD; SINGLE DRUG DOSE; SURVIVAL; SURVIVAL RATE; YOUNG ADULT; ANALOGS AND DERIVATIVES; ANIMAL; CELL HYPOXIA; CELL PROLIFERATION; DISEASE MODEL; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; METABOLISM; PATHOLOGY; PULMONARY ARTERY; SMOOTH MUSCLE CELL; SPRAGUE DAWLEY RAT; TIME FACTOR;

ADOLESCENT; ADULT; ANIMALS; CELL HYPOXIA; CELL PROLIFERATION; CHILD; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MONOCROTALINE; MYOCYTES, SMOOTH MUSCLE; NANOPARTICLES; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; YOUNG ADULT;

EID: 84953807453     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000352     Document Type: Article

References (22)

1. Humbert M, Lau EM, Montani D, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130:2189-2208.
2. Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
3. Starling MB, Neutze JM, Elliott RL. Control of elevated pulmonary vascular resistance in neonatal swine with prostacyclin (pgi2). Prostaglandins Med. 1979;3:105-117.
4. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485-491.
5. Barst RJ, Rubin LJ, Long WA, et al; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
6. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788.
7. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106: 1477-1482.
8. Akagi S, Matsubara H, Ogawa A, et al. Prevention of catheter-related infections using a closed hub system in patients with pulmonary arterial hypertension. Circ J. 2007;71:559-564.
9. Davies S, McKenna F, Turney J, et al. Severe hypotension due to epoprostenol. Lancet. 1984;2:1401-1402.
10. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010;363: 2434-2443.
11. Akagi S, Nakamura K, Miura D, et al. Delivery of imatinibincorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension. Int Heart J. 2015;56:354-359.
12. Akagi S, Nakamura K, Miyaji K, et al. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J. 2010;74:2200-2205.
13. Akagi S, Nakamura K, Matsubara H, et al. Prostaglandin i2 induces apoptosis via upregulation of fas ligand in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol. 2013;165:499-505.
14. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German pph study group. J Am Coll Cardiol. 2000;35:176-182.
15. Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-1870.
16. Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010;104:731-740.
17. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329.
18. Matoba T, Egashira K. Nanoparticle-mediated drug delivery system for cardiovascular disease. Int Heart J. 2014;55:281-286.
19. Kimura S, Egashira K, Chen L, et al. Nanoparticle-mediated delivery of nuclear factor kappab decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension. 2009;53:877-883.
20. Chen L, Nakano K, Kimura S, et al. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension. 2011;57:343-350.
21. Clapp LH, Finney P, Turcato S, et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic amp generation in human pulmonary artery. Am J Respir Cell Mol Biol. 2002;26:194-201.
22. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:2119-2125.